

majority of instances heal themselves after repair of the hernia. They occur at the columnal squamous junction rather than at the gastro-esophageal junction and in those cases which do not spontaneously heal, a few esophageal dilations are generally sufficient to overcome the narrowing of the esophagus provided the hiatal hernia repair is adequate.

ANGELO MAY, MD

REFERENCES

- Skinner DB: Gastroesophageal Reflux and Hiatal Hernia. Boston, Little Brown & Co, 1972
Hill LD: Management of recurrent hiatal hernia. Arch Surg 102: 296, Apr 1971
Ellis FH: Technique of fundoplication. Surg Clin North Am 51:3, Jun 1971
Payne WS: Esophageal reflux ulceration—Causes and surgical management. Surg Clin North Am 51:935, Aug 1971

Lung Oxidant Toxicity

IN CERTAIN EXPERIMENTAL and clinical situations inhalation of oxidants, including both oxygen at tensions considerably above ambient levels and the pollutant oxidants (ozone and oxides of nitrogen) leads to "diffuse bronchio-alveolar damage." Although temporal pathological studies of oxidant-induced lesions in man are meager and the relationship of pulmonary O₂ cytotoxicity to the toxic effects of pollutant oxidants is still unclear, available studies indicate that excessive oxidant exposure causes damage to bronchial mucosa, alveolar epithelium, and capillary endothelium resulting in bronchio-alveolar inflammation and edema. The precise time-dose relationship for the three oxidants is not well defined in man. Experimental and clinical observations suggest a wide range of species and individual susceptibility or resistance to oxidant damage. In addition, tolerance and cross-tolerance to a toxic oxidant level after prolonged low-dose or acute intermittent-dose oxidant exposure has been noted. Although the critical mode of interaction between oxidants and lung cells is still unclear, excessive oxidant

exposure can be expected to cause loss of cellular reducing equivalents and unsaturated lipid oxidation, presumably via free radical mechanisms.

Oxidant damage occurs coincident with oxidant interaction with lung cellular oxido-reductive processes and inactivation of enzymatic thiol groups. Recent studies have suggested that the lung contains a reservoir of thiol protective substances (for example, glutathione) and that this reservoir can be compromised or augmented under certain conditions . . . a function of oxidative-protective thiols analogous to those of erythrocytes. Further studies have emphasized the presence in lung tissue of oxidant detoxification mechanisms that potentially function to dissipate the toxic products of lipid peroxidation. Indeed, in tolerance-producing situations these mechanisms show an augmented ability to detoxify lipid peroxides via the glutathione peroxidase mechanism.

Lung enzymatic adaptations may determine lung resistance to oxidant damage . . . increased oxidant levels may induce an augmentation of these lung antioxidant defense mechanisms. Biochemical studies of tissue may be a simple but sensitive indicator for detecting lung oxidant damage. Although current studies are not sufficient by themselves to lead to a unitary version of lung oxidant damage, they indicate a clear program of experiments to test the significance of oxidant induced lung metabolic perturbations and suggest mechanisms of potentially treating these syndromes.

CARROLL E. CROSS, MD

REFERENCES

- Stokinger HE, Coffin DL: Biologic effects of air pollutants, In Stern AC (Ed): Air Pollution, 2nd Ed. New York, Academic Press, 1968, Vol 1, pp 401-546
Menzel DB: Toxicity of ozone, oxygen and radiation. Annu Rev Pharmacol 10:379-394, 1970
DeLucia AJ, Hoque PM, Mustafa MD, et al: Ozone interaction with rodent lung: Effect on sulfhydryls and sulfhydryl-containing enzyme activities. J Lab Clin Med 80:559-566, Sep 1972
Chow CK, Tappel AL: An enzymatic protective mechanism against lipid peroxidation damage to lungs of ozone-exposed rats. Lipids 7:518-524, Aug 1972

ADVISORY PANEL TO THE SECTION ON CHEST DISEASES

HANS EINSTEIN, MD, *Chairman, Bakersfield*
CMA Scientific Board

ANGELO MAY, MD
CMA Section on Chest Diseases
Chairman
San Francisco

OSCAR BALCHUM, MD
CMA Section on Chest Diseases
Secretary
Los Angeles

ARCHIE WILSON, MD
University of California, Irvine
California College of Medicine

DANIEL SIMMONS, MD
University of California, Los Angeles

FREDERIC ELDRIDGE, MD
Stanford University

DAVID C. RAUSCH, MD
University of California, Davis

WARREN GOLD, MD
University of California, San Francisco

KENNETH M. MOSER, MD
University of California, San Diego

STANLEY ROKAW, MD
Los Angeles

JOHN HODGKIN, MD
Loma Linda University

BUFORD H. WARDRIP, MD
San Jose

WILBER HALLET, MD
CMA Section on Chest Diseases
Assistant Secretary
Burbank